NEW YORK, Oct. 10, 2006 (PRIMEZONE) -- National Stem Cell Holding, Inc. (Pink Sheets:NHGI), a biotech company, announced today that Dr. Shulamit Levenberg, a Senior Lecturer of Biomedical Engineering and Director of the Human Embryonic Stem Cell Tissue Engineering laboratory at the Technion -- Israel Institute of Technology, has joined the company's Scientific Advisory Board, which was established to guide the stem cell research and development initiatives of National Stem Cell.
A leading researcher in the fields of stem cell tissue engineering and bio polymers as well as molecular and cellular biology, Dr. Levenberg co-authored a 2003 academic paper as a post-doctorate fellow and research associate with MIT's Chemical Engineering Department detailing a new approach to creating three-dimensional samples of human tissues. She has been awarded the EMBO and Fulbright scholarships as a post-doctorate fellow, the ASAIO William J. Kolff Young Investigators Award, the Marie-Curie International Reintegration fellowship and the Wolf Foundation's 2006 Krill prize for excellence in scientific research.
"Dr. Levenberg's dedication and research excellence, in addition to her background in bio polymers, will help guide our efforts developing new stem cell therapies for a wide range of diseases," explains Michael Cohen, CEO of National Stem Cell. "We are thrilled she has agreed to join our Scientific Advisory Board and look forward to integrating her into our team."
About National Stem Cell Holding, Inc.
National Stem Cell Holding, Inc. (Pink Sheets:NHGI) is a biotechnology company headquartered in New York City dedicated to the advancement of regenerative medicine. Incorporated in 2005, National Stem Cell Holding is the parent company of National Stem Cell, Inc. ("NSCI"), which operates the Sperm Bank of New York as a wholly owned subsidiary. Through its sponsored research agreement with the Johns Hopkins University School of Medicine's Institute for Cell Engineering ("ICE"), NSCI is focused on the development of potential stem cell therapies for the treatment of diabetes and cardiac injury. The company also plans to develop a genetically diverse umbilical cord blood bank to meet the growing need for transplant grade umbilical cord blood stem cells. For more information, please visit www.nationalstemcell.com.